ASX - By Stock
|
LOT |
Re:
Uranium news
|
|
Sentisure
|
84 |
39K |
0 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
84
|
39K
|
0
|
|
ASX - By Stock
|
MEI |
Re:
Meteoric Resources - Caldeira Review
|
|
Sentisure
|
14 |
5.0K |
5 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
14
|
5.0K
|
5
|
|
ASX - By Stock
|
MEI |
Re:
General discussion (MEI)
|
|
Sentisure
|
4.8K |
1.8M |
7 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
4.8K
|
1.8M
|
7
|
|
ASX - By Stock
|
EPM |
Re:
Ann: Investor Presentation
|
|
Sentisure
|
23 |
6.7K |
8 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
23
|
6.7K
|
8
|
|
ASX - By Stock
|
EMP |
Re:
Ann: Results of Judith-1 Well Gas Production Simulation Modelling
|
|
Sentisure
|
24 |
5.4K |
0 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
24
|
5.4K
|
0
|
|
ASX - By Stock
|
COE |
Re:
Ann: Q3 FY24 Quarterly Report
|
|
Sentisure
|
10 |
5.0K |
5 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
10
|
5.0K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Medium term milestones
|
|
Sentisure
|
89 |
45K |
20 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
89
|
45K
|
20
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Imugene and Kincell Bio Announce Strategic Partnership
|
|
Sentisure
|
144 |
65K |
5 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
144
|
65K
|
5
|
|
ASX - By Stock
|
COE |
Re:
Ann: Q3 Quarterly report conference call details
|
|
Sentisure
|
2 |
1.1K |
11 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
2
|
1.1K
|
11
|
|
ASX - By Stock
|
IDX |
Re:
Ann: Half Year Results Investor Presentation
|
|
Sentisure
|
11 |
6.7K |
0 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
11
|
6.7K
|
0
|
|
ASX - By Stock
|
COE |
Re:
Ann: Market Update
|
|
Sentisure
|
13 |
5.8K |
5 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
13
|
5.8K
|
5
|
|
ASX - By Stock
|
MEI |
Re:
General discussion (MEI)
|
|
Sentisure
|
4.8K |
1.8M |
12 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
4.8K
|
1.8M
|
12
|
|
ASX - By Stock
|
IMU |
Re:
Media Thread
|
|
Sentisure
|
13K |
6.5M |
17 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
13K
|
6.5M
|
17
|
|
ASX - By Stock
|
COE |
Re:
Ann: Cooper Energy H1 FY24 results presentation
|
|
Sentisure
|
56 |
22K |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
56
|
22K
|
2
|
|
ASX - By Stock
|
RIC |
Re:
Ann: Change in substantial holding
|
|
Sentisure
|
2 |
651 |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
2
|
651
|
2
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Appointment of Debt Advisor for Kayelekera Restart
|
|
Sentisure
|
3 |
1.2K |
7 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
3
|
1.2K
|
7
|
|
ASX - By Stock
|
MEI |
Re:
General discussion (MEI)
|
|
Sentisure
|
4.8K |
1.8M |
15 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
4.8K
|
1.8M
|
15
|
|
ASX - By Stock
|
COE |
Re:
Ann: Cooper Energy H1 FY24 results presentation
|
|
Sentisure
|
56 |
22K |
5 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
56
|
22K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Sentisure
|
557 |
206K |
5 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
557
|
206K
|
5
|
|
ASX - By Stock
|
COE |
Re:
Ann: Cooper Energy H1 FY24 results presentation
|
|
Sentisure
|
56 |
22K |
0 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
56
|
22K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
Sentisure
|
78 |
24K |
5 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
24K
|
5
|
|
ASX - By Stock
|
COE |
Re:
Ann: Cooper Energy H1 FY24 results presentation
|
|
Sentisure
|
56 |
22K |
6 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
56
|
22K
|
6
|
|
ASX - By Stock
|
PNV |
Re:
Ann: Largest ever single order
|
|
Sentisure
|
94 |
37K |
6 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
94
|
37K
|
6
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient
|
|
Sentisure
|
104 |
59K |
17 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
104
|
59K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
Sentisure
|
316 |
162K |
25 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
316
|
162K
|
25
|
|
ASX - By Stock
|
ATH |
Re:
Finally Moving North
|
|
Sentisure
|
15 |
3.6K |
2 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
15
|
3.6K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Phase 2 DMC Recommends Continuing Clinical Trial as Planned
|
|
Sentisure
|
8 |
2.6K |
5 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
8
|
2.6K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation for Revascor
|
|
Sentisure
|
380 |
127K |
6 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
380
|
127K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Sentisure
|
9.6K |
2.8M |
15 |
22/12/23 |
22/12/23 |
ASX - By Stock
|
9.6K
|
2.8M
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Completion of enrolment in Neuren's Angelman P2 trial
|
|
Sentisure
|
51 |
32K |
19 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
51
|
32K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Entitlement Offer and Placement Investor Presentation
|
|
Sentisure
|
48 |
15K |
3 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
48
|
15K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
Sentisure
|
208 |
85K |
4 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
208
|
85K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
Sentisure
|
208 |
85K |
9 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
208
|
85K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
Sentisure
|
315 |
156K |
9 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
315
|
156K
|
9
|
|